insitro, South San Francisco, CA, Hybrid
The unprecedented convergence of multi-modal data, advanced disease modeling, and computational power is revolutionizing drug discovery. insitro is harnessing this moment to redefine how medicines are developed for complex diseases. Our AI/ML-enabled platforms integrate and scale data to rapidly discover novel biological insights to redefine complex diseases and identify new targets and drugs. To enable this vision we are seeking a Senior Director / Vice President of Clinical Operations who will build an AI-forward operations capability.
This role will partner with Discovery, Translational Medicine, Technical Operations, Clinical, Regulatory, External R&D, Biostatistics and Procurement teams to directly improve patients' lives by leading clinical trial operations across neurological, ophthalmological and metabolic indications, advancing innovative medicines and diagnostics in a patient-focused way.
You will lead the Clinical Operations function at insitro; implementing clinical operations strategies to support the development of multiple therapeutics and diagnostics. Identification of the right patients, enrolling them efficiently, and acquiring robust clinical data to inform decision making remain key challenges for clinical trial operations. You will be at the forefront of designing and implementing innovative, accelerated operations approaches, and you will have the opportunity to utilize insitro's machine learning expertise to achieve operational excellence.
You will report directly to the Chief Medical Officer. This role can be either onsite (3 days per week) in our South San Francisco office or hybrid (~1 week per month) in our office. Additional travel may be needed to relevant medical and health authorities, study sites etc.
This is an excellent opportunity for a seasoned Clinical Operations professional who is passionate about using their skills and experience to accelerate the drug development process and bring better drugs to the patients who can benefit most.
Our target starting salary for successful US-based applicants for this role is $259,000 - $312,000. To determine starting pay, we consider multiple job-related factors including a candidate's skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data.
This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.
In addition, insitro also provides our employees:
insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.
We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.
_Please be aware of recruitment scams: we never request payments, all recruitment communications are from @_[_insitro.com_](http://insitro.com) _, and if in doubt, contact us at_ __info@insitro.com__ _._
insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit [www.insitro.com](http://www.insitro.com).
Insitro is an AI-driven drug discovery and development company leveraging machine learning and large-scale biological data to create better medicines faster.
View company profile →